Downloading...
Download

Shroomboom

Deeply oversold/undervalued psychedelics playPsychedelics space has seen some multi-baggers in the span of the last 2 weeks, suggesting investors are once again starting to pour money into speculative shroom stocks. CSE:LVT is deeply oversold (RSI @ 22.69), hitting all time lows. The company is deeply fundamentally undervalued: - $1.87M market cap - Raised $1.5M at 0.20 in February - Generating revenue of over $2M per quarter Some comparable psychedelic companies with less revenue are trading at more than 10x. Unless there's some kind of fundamental/unknown reason for recent selloff, other than weak general markets, this is a potential multi-bagger candidate from current levels, in my humble opinion. GLTA
CSE:LVTLong
by agstockpicks
We'll the 4.20s soon.Has been a tripp , right? It ain't easy to transition an entire underground movement into a legal bureaucratic compelling business. There's so much potential for these companies. So let's look at the recent price movement. The DMI shows we reached equilibrium around the mid 4s, if we get a broader market uptrend we'll highly likely see our favorite number 4.20. Exceptional volume has shown up meaning an uptrend is forming. If the ship is steady (RSI) well probably could see 5s again end of month. Let's set sail!
FLong
by dodobirdflyup
Possible Wykoff accum. after price discovery - NUMI shroomboomNUMI could be in the midst of a Wykoff accumulation. ^ means a pro, v means a con. I am trying to look at both sides to reduce emotionally-blinded decision making. Looking from far, there is systematic market risk: v institutions adopting Bitcoin, resulting in broad market exposure to USDT fraud risk and Bitcoin volatility v GME apes stressing underlying system A broader market pullback or turn to bear market can affect any stock's price. Looking at the sector: ^ I believe I know that psychedelics work, and are safe ^ mental health a huge industry that impacts all sectors because..humans, and looks to grow due to COVID v proper testing can take time and money v Canadian election can affect the path the sector takes. I believe the psychedelics market is in the nascent stages of a multi-year bull market. Valuing companies in the sector right now is difficult. Looking at the company: ^ one of the few companies in the sector that actually has revenue ^ lower risk of `going to zero` because not focused on novel compounds ^ is focused on creating IP v lower potential to moon because not focused on patenting compounds v rank-ordered within industry, less focused on making money, more focused on helping people and making help accessible ^ outstanding team and network ^ focused on psychedelic-assisted psychotherapy (similar to shamanic-assisted tripping, which is an ancient, proven methodology) ^ $63.2 million cash position (1/3 current market value @~$0.87 ^ YOY revenue is expected to increase by ~100% v not much attention on reddit (hey, it seems to matter) ^ lower volatility due to lack of meme-retail involvement v has diluted shares in the past The company is solid, growing through acquisitions and research, and a leader in the sector. Numinus is licence by Health Canada to cultivate, extract and sell psychedelic compounds. They also have a dealer's licence to import, export, possess, test and distribute MDMA, psilocybin, psilocin, DMT and mescaline. v my understanding is that ibogaine is the most effective psychedelic specifically for opioid addiction. but entails cardiac risk, but numinus does not seem to be working with ibogaine-derived compounds The book: Bear Market Trading Strategies by Matthew R Kratter say that if a stock moves above it's 200 day MA, one can consider shorting. Playing with this logic, NUMI is below it's 200 day MA in what looks to be a possible multi-year bull market, so now might be a good entry point. On morality and ethics: Numinus may not have a 1B valuation like MMED (with 0 revenue), but by supporting a company that is focused on natural healing and accessibility it is a step in a direction away from the big pharma method of `extracting value from` towards the team human (podcast) method of `creating value for`. And I believe that is what the mushrooms want :). How does investing help Numinus Wellness: A higher stock price allows for things such as uplisting to the TSX and NYSE which gives them more access to capital. Also, investor support allows them to obtain capital at a higher valuation. Full disclosure: I bought NUMI at 28c, have sold off portions several time for a variety of reasons, and now am dollar cost averaging in again during sideways movement and am focusing on managing risk. This is my first chart publish. I will appreciate all feedback, critical or otherwise. This is not financial advice.
NLong
by jtorkr
12
BETR -- Brought down by .40 PP; rebound likely after flushThis psychedelics play has been selling off after announcing a private placement at .40. Just out of oversold area and close to completing a bullish MACD cross. My guess is that some of the financing participants are selling their .40 shares and keeping the free .50 warrant which creates an opportunity to get in at discount to financing. Management is highly promotional. They managed to run it up 4x following the previous financing. Could see something similar play out, especially if psychedelics sector gets hot again.
CSE:BETRLong
by agstockpicks
Pharma Patent Law Party Time!! $PHRRFSo here's my guess for the next short term bout of fun and awesome small cap volatility! Seriously though, I like how this company operates so far. Protective patents have been filed, they've already set up plenty of partnerships to get clinical trials rolling, and the blue-sky potential here is pretty staggering. No, really, it's suspiciously good. I'm obviously kinda dumb though, so it could just be a "stuck in my own thrall" kinda situation. Ok for starters, I'll admit that I don't care about the patent stuff. I'll explain why: I'm confident that the microneedle patch is protective enough that the whole issue of 'method of treatment' patents is negligible. But everyone is going to see "Clinical Trials for Big Disease! Big Yes!" Then they see it's for a generic drug and are all, "well that isn't how you print money!" and they scurry back into their dark abyss. Ok, so say it with me: " proprietary patch is patent protected." Don't worry, I'm totally gonna forget, too! But even aside from that, there is a (relatively-recent!) precedent set for patent protections in regards to "Methods of Treatment." It's a whole 'thing' that I'm not qualified to talk about, but I'm doing my own due diligence. Without looking though, I can say that a court case settled in 2018 is new by law standards, and new laws are frequently subject to challenges. For this reason, I'm gonna go ahead and anticipate a (temporary, brief) further drop in share price until everyone brushes up on the relevant patent cases. When everyone's homework gets turned in, I'm thinking we'll see $0.45USD. Idk, I really like when projected patterns line up with good fundamental markers- bonus points for ending on or near pretty, round numbers. I've gotta admit though, it's definitely feels like a stupid way to think, so it's probably dangerous to share the notion. Caveat stultus and all that. Regardless, the company still has a ridiculously small market cap when compared to other equivalent players in the psychedelic pharmaceutical space. Yeah, even after the recent gains. (To be fair, it could just mean that everyone else has much more room to fall.) Anyway! Let me know if I need to stop! :)
OTC:PHRRFLong
by pleasesendhel
Literally The Most Undervalued "Shroom Stock?"I mean look, I know it's all a bunch of speculative mumbo jumbo, but some of these other psychedelic companies have like, BILLION dollar market caps! That's crazy, right? I mean sure, they will certainly disrupt an incredibly-entrenched industry, but it's going to take time for that to happen... That said, I think there are going to be baby steps, which means they're going to work with what they know is effective in the "now." So yeah, ketamine. I'm not a huge fan either, but it's super difficult to ignore it's efficacy in the face of all the facts. I know it's contraindicated for certain individuals, but I still believe there's an avenue for success available for novel formulations. It all looks wacky and appears at first to be pseudoscience, but we're talking about research methods (like PanaceAI) that have been under development for years. It's crazy until it happens, and then it's useful. And it's more than icing on the cake that ketamine is a candidate for the treatment of a whole litany of movement disorders such as ALS. Iiii know, vile, evil drugs are bad and horrible. They'll certainly kill us all, as they always have. But seriously, look into a few things before you scoff at reality. "NMDA receptor antagonist," "parkinson's LID ketamine," "ketamine glutamate." Oh, I mentioned market caps. There's a fundamental reason to pay close attention here: as of right now (5/2/21), it's looking like a little north of $14 million USD. The company already had a pre-IND meeting with the FDA regarding their first Phase II trial, and as noted in the chart, the announcement was made on 4/20. For those that aren't aware, this means that the company will be permitted to commence their trials as soon as 5/21, provided that the FDA does not deny the IND request. 8 sites, up to 36 patients.. based on "no-brainer" data. Catalyst one. Let me know how wrong I am about this, please. I am begging you to give me a counterpoint here, because I've dug and dug and haven't found it yet.
OTC:PHRRFLong
by pleasesendhel
TRIP.C is starting another leg up on Brazil expansion newsTRIP had a major news release today, having its psychedelic products authorized for import to Brazil. The stock has consolidated well and is forming a Double Bottom (bullish biased) pattern on the daily chart. Promotional campaign is under way. I am in at .495. -- Red Light Holland iMicrodose Pack Receives Authorization for the First Legal Import and Sale of Psilocybin Truffles to Brazil Anvisa, The Brazilian Health Regulatory Agency has granted a permit to import the Company's iMicrodose Pack by way of the Country's 'named patient import process' for prescribed medical use Toronto, Ontario--(Newsfile Corp. - February 25, 2021) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands, is extremely pleased to announce that Anvisa, Brazil's National Health Regulatory Agency, has granted authorization for the Company's iMicrodose packs, which contain 15g of Psilocybin Truffles, to be legally imported to Brazil via the 'named patient import process' for prescribed medical patient use. "We are grateful for our collaborative relationship with Disruptive Pharma who worked closely with the Brazilian Health Regulatory Agency to secure authorization to import Red Light Holland's iMicrodose packs, with our natural-occurring branded Psilocybin Truffles, to be imported and sold in Brazil for Medical use, as our branded iMicrodose packs have officially been prescribed by a doctor to a patient in Brazil," said Todd Shapiro, CEO and Director of Red Light Holland. "This is a monumental day for the Company, and we are so proud to be a part of providing legal access of psilocybin to Brazil and for the first time having our product prescribed by a physician for medical use." Red Light Holland's iMicrodose packs have been shipped to Disruptive Pharma's MyPharma2Go logistics hub in the Netherlands to start their journey to Brazil. Once landed in Brazil, MyPharma2Go is expected to deliver the iMicrodose packs to a Brazilian patient as they have been pre-prescribed by a physician, before the end of March 2021. This approval and shipment represent a significant advancement in opening the legal and medically approved market for psilocybin in Brazil, a country with a population of over 200 million people. Shapiro added: "This early process working alongside Disruptive Pharma's MyPharma2Go.com, a large Brazilian online pharmaceutical and supplement distributor, has been an absolute pleasure and one we are thankful for. We are pleased to do our part to potentially be a part of positive change in Brazil, and to steal a line from Neil Armstrong: This is one micro step for man, one macro leap for mankind." Red Light Holland and Disruptive Pharma continue to work towards finalizing their proposed joint venture structure and agreement, as previously disclosed in the Company's news release dated December 14, 2020. In consideration for Disruptive Pharma having met these initial milestones, the Company has agreed to issue to Disruptive Pharma, 3,000,000 common share purchase warrants, each warrant is exercisable into one common share of the Company at a price of $0.50 per share for a period of 2 years. 750,000 of these warrants have vested immediately based on Disruptive Pharma having fulfilled these milestones, the balance vest upon future milestones being met. These warrants and any underlying shares issued upon exercise, are subject to a statutory hold period of 4 months and 1 day.
CSE:TRIP
by agstockpicks
5
CMPS - The Shroom BoomThere are now talks on wall street bets about the coming "Shroom Boom" The two biggest players are MMEDF and CMPS. CMPS is backed by Peter Thiel and MMEDF is backed by Kevin OLeary. CMPS is my preferred play since they are already on the Nasdaq and offer options. We can clearly see the trend line (purple) is holding very strong and has been tested multiple times. The regression trend is weak, but the price is starting to move back up the retracement levels and above the strong level of support around 45 (blue line.) Yesterdays buy volume was high for all of the stocks in the industry (callout box). I believe big players are pushing into this sector and soon will begin a marketing campaign to push these stocks even higher. Don't forget to cash out when it hits the mainstream.
NASDAQ:CMPSLong
by ArchersWingman
2